B I O T E C H N O L O G Y A N D L I F E S C I E N C E S

T h e G r e a t e r R o c h e s t e rN

e wYo r k

Re

gi o

n

RANKED 4 T H AMONG 125 WORLD REGIONS FOR “ WORLD KNOW LEDGE COMPETITIVENESS”

Robert Huggins Associates, 2003

H O M E TO O V E R 7 0 B I O T E C H N O L O G Y A N D L I F E S C I E N C E S R E L AT E DC O M P A N I E S E M P L O Y I N G O V E R 7, 0 0 0 W O R K E R S

HOM E TO S H A R P MIN D S , DIS C O V E RIE S A N D S TAT E- OF-T H E- A RTR E S E A R C H FA CILI T IE S A N D E DUC AT ION A L INS T I T U T IONS :

C E N T E R FOR E LEC TRONI C IM A GING S Y S T E MS

COR N E LL A GRI C U LT U R E A N D FO OD T EC H NOLO G Y PA R K

IN FOTONI C S T EC H NOLO G Y C E N T E R

RO C H E S T E R INS T I T U T E OF T EC H NOLO G Y

U NI V E R S I T Y OF RO C H E S T E R M E DI C A L C E N T E R

OU T S TA N DING QU A LI T Y OF LIFE — ON E OF T E N BE S T CI T IE S TO R A IS E A FA MILY A N D VA C AT IONChild Magazine, 2003; Money Magazine, 2002

R A N K E D A M O N G T H E T O P 4 0 U . S . B I O T E C H L O C A T I O N S

Business Facilities: The Location Advisor, 2003

R A N K E D 1 S T F O R U T I L I T Y P AT E N T S I S S U E D TO C O M P A N I E S O R I N D I V I D U A L S P E R 1 , 0 0 0 W O R K E R S

Metropolitan New Economy Index, 2003

R A N K E D 3 R D F O R N U M B E R O F C O L L E G E G R A D U A T E S W I T H L I F E S C I E N C E D E G R E E S P E R C A P I T A

U.S. Department of Education, 2001

WHAT’S THE LATEST DISCOVERY IN

BIOTECHNOLOGY AND LIFE SCIENCES?

THE GREATER ROCHESTER

NEW YORK REGION.

R E G I O N A L O V E R V I E W . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1

U N I V E R S I T Y O F R O C H E S T E R M E D I C A L C E N T E R . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

R O C H E S T E R I N S T I T U T E O F T E C H N O L O G Y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

I N F O T O N I C S T E C H N O L O G Y C E N T E R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3

C E N T E R F O R E L E C T R O N I C I M A G I N G S Y S T E M S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3

C O R N E L L A G R I C U L T U R E A N D F O O D T E C H N O L O G Y P A R K . . . . . . . . . . . . . . . 1 4

N A T I O N A L I N D U S T R Y T R E N D S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 5

I N C E N T I V E S A N D F I N A N C I N G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 7

T O P R E G I O N A L B I O T E C H N O L O G Y / L I F E S C I E N C E S C O M P A N I E S . . . . . . . . . 1 8

R E G I O N A L B I O T E C H N O L O G Y / L I F E S C I E N C E S W E B S I T E S . . . . . . . . . . . . . . . . 2 4

W H A T ’ S I N S I D E

I f you're searching for a perfect location to

conduct research, c l inical t r ials and advanced

biotechnology manufacturing, look no fur ther.

Home to state-of-the-ar t research

faci l i t ies and educational inst i tut ions, a high level

of innovation and entrepreneurial spir i t ,

an outstanding qual i ty of l i fe and numerous tax benefits

for biotechnology and l i fe sciences companies —

discover for yourself why the

Greater Rochester New York Region is ideal for you.

1

Ranked 3rd for number of college graduates with Life Science degrees per capita

U.S. Department of Education, 2001

Ranked among the Top 40 U.S. Biotech Locations Business Facilities: The Location Advisor, 2003

The study identified the best locations for biotechnology, life sciences, and pharmaceutical companies.

Ranked among America’s 50 Hottest Cities for Business Expansions and RelocationsExpansion Management, 2004

Seventy of the industry’s most prominent site selection consultants were surveyed to rank 50 of the most attractive cities for business expansion or relocation among 370 metro areas.

Home to over 70 Biotechnology and Life Sciences industry related firms that employ over 7,000 workers in the region

Top Biotechnology and Life Sciences Firms: Bausch & Lomb; Biophan Technologies, Inc.; Celltech Pharmaceuticals Inc., the U.S. headquarters of a leadingEuropean biotechnology company; Genencor International, Inc.; Getinge USA Inc.; Integrated Nano-Technologies;Eastman Kodak Company Health Imaging; Ortho-Clinical Diagnostics, a Johnson & Johnson company; STS duoTEK, Inc.; and VirtualScopics LLC.

Relative Industry Size: Industry strength within metropolitan areas is measured by a location quotient (LQ) index. Rochester’s LQ for the Biotechnology and Life Sciences Industry is 1.0, meaning industry employmentmatched the U.S. average of 1.0. Yet, Medical Equipment and Supplies, a sub-sector, has an LQ of 2.3, indicating employment is more than twice as large as the U.S. average.

Ease of Access to Key Markets: Daily non-stop flights of less than one hour to Washington-Baltimore, New York-New Jersey, Boston and Philadelphia.

Various research centers and institutes support university-business partnerships and R&D activities.

University Commitment to Biotechnology

• Rochester Institute of Technology (RIT) established the first biotechnology Bachelor’s program in the U.S. in1983 and continues to be a national model. RIT also recently introduced new Bachelor’s and Master’s Degreeprograms in bioinformatics, and is building a new 38,000 square foot Center for Biotechnology Education andTraining. The $12 million facility is being built with $8 million in funding from New York State.

• In 2002, the University of Rochester received a $30 million New York State grant to support space and start-upcapital for emerging biotech firms. This is part of a ten-year, $550 million initiative to dramatically expandmedical research.

A N E M E R G I N G B I OT E C H N O LO G Y A N D LI F E S C I E N C E S I N D U S T R Y H U B

G R E A T E R R O C H E S T E R

Ranked 5th for Overall Innovation Capacity among 50 U.S. metro areasMetropolitan New Economy Index, 2001

Overall Innovation Capacity Criteria:1. Jobs in high-tech industries 2. Degrees granted in science and engineering 3. Number of patents4. Academic research and development funding5. Venture capital invested

Ranked #1 for utility patents issued to companies or individuals per 1,000 workers Metropolitan New Economy Index, 2003

New York State consistently ranks among the top three states for venture capital investments in the U.S. American Electronics Association, Cyberstates, 2001

Ranked 4th among 125 world regions for “World Knowledge Competitiveness” Robert Huggins Associates, 2003

U N I V E R S I T Y R E S E A R C H A N D D E V E LO P M E N T

University of Rochester Research: In fiscal 2003, the University of Rochester attracted $308.1 millionin research grants, up 22% from $252.7 million a year ago. Of the 2003 amount, the University ofRochester Medical Center attracted $202.5 million of those research grants.

University of Rochester, 2004

The University of Rochester ranked among the top 10% of national research universities forannual Research and Development expenditures National Science Foundation, 2000

University of Rochester ranked among the top three universities nationwide, based on the impactof its patents MIT Technology Review: TR University Technology Scorecard, 2003

University of Rochester ranked 6th in Licensing Revenue among U.S. academic institutionsAssociation of University Technology Managers, 2003

At $42 million, the University of Rochester ranked among the top academic institutions in the nationin earning revenue from the research of university scientists and engineers during FY 2002.

Rochester Institute of Technology:With over 15,000 students, 360 degree programs and 30 research laboratories and centers, RIT has significantly grown its research in areas of excellence including Imaging Science, Microsystems and Sustainable Design. This increase of over 300% in five years provides a growing capability to the Biotechnology and Life Sciences community.

2

REGIONAL

OVERVIEW

A L E A D E R I N D I S C O V E R Y A N D I N N O VAT I O N

N E W Y O R K R E G I O N

E M P LOY M E N T • BIOT EC H NOLO GY A N D LIFE S CIE NC E S • 20 02

Greater NAICS Industry Rochester

3254 Pharmaceutical and Medicine Manufacturing 43054171 R&D in Physical, Engineering and Life Sciences 60633451 Medical and Control Instruments 2,47033911 Medical Equipment and Supplies Manufacturing 2,94062151 Medical and Diagnostic Labs 730

Total 7,176Source: Bureau of Labor Statistics/NYDOL

LO C AT ION QUOT IE N T • 20 02

Location NAICS Industry Quotient

3254 Pharmaceutical and Medicine Manufacturing 0.454171 R&D in Physical, Engineering and Life Sciences 0.333451 Medical and Control Instruments 1.333911 Medical Equipment and Supplies Manufacturing 2.362151 Medical and Diagnostic Labs 1.0

Source: Calculated using 2002 BLS/NYDOL data

U.S. Location Quotient is equivalent to 1.0

BIOT EC H NOLO GY A N D LIFE S CIE NC E S R E L AT E D DEGR E E S CON FE R R E DIN T H E GR E AT E R RO C H E S T E R N E W YOR K R EGION • 20 02

FirstBiotech/Life Sciences Related Degree Program Associate Bachelor Masters Doctoral Professional TotalBiological Sciences/Life Sciences 0 490 81 34 0 605Physical Sciences 1 190 51 20 0 262Health Professions and Related Sciences 57 253 75 4 339 728Science Technologies 14 0 0 0 0 14Engineering and Engineering-Related Technologies 341 712 167 16 0 1,236Computer and Information Sciences 294 231 82 5 0 612Mathematics 0 169 18 3 0 190Total Biotech Related Degrees 707 2,045 474 82 339 3,647

Source: NYSED Office of Research and Information Systems: Data from Federal IPEDS Survey C, 2002

N E W YOR K S TAT EBIOT EC H NOLO GY A S S O CI AT IONS

New York Biotechnology Association

Biotechnology Industry Association

Healthcare Industries Association

AMDeC Foundation, Inc.

REGIONAL

OVERVIEW

3

UNIVERSIT Y OF

ROCHESTER

MEDICAL CENTER

4

U NI V E R SI T Y OFRO C H E S T E R M E DI C A L C E N T E R

With more than one million square feet of research facilities across seven buildings and $135 million in funding from the National Institutes of Health last year, theUniversity of Rochester School of Medicine and Dentistry ranks in the top 25% of medical schools in the most recent NIH rankings. The research programs in Neurologyand Orthopaedics rank in the top five nationally, and the program in Microbiology andImmunology ranks 11th.

More than 2,500 people at the Medical Center are employed as medical researchersincluding physicians, molecular biologists, statisticians, technicians, and other supportpersonnel. A recent half-billion-dollar expansion of the research programs added twonew research buildings and 70 Ph.D.-level scientists over the past five years.

The Nobel Prize in Medicine has been awarded four times to faculty and graduates of the Universityof Rochester School of Medicine and Dentistry. University of Rochester researchers discovered thecox-2 enzyme, which laid the groundwork for the new class of arthritis medications that includesCelebrex. Researchers also developed the HiB vaccine against bacterial meningitis, now universallyrecommended for young children, reducing the rate of the disease by 95% in the U.S.

601 Elmwood Avenue Rochester NY, 14642 www.urmc.rochester.edu

For information contact: Marjorie Hunter, Director, Technology Transfer 585-784-8850Marjorie_Hunter@URMC.Rochester.edu

Christopher DiFrancesco, Director, Research Communications 585-273-4790 Chris_Difrancesco@URMC.Rochester.edu

Re s ea r c h C enter s a nd C o r e Fac i l i t ie s

Aab Institute of Biomedical Sciences is the centerpiece of a 10-year, $500 million strategic plan to expandthe Medical Center's research programs in the basic sciences. The Institute is organized into six interdisciplinaryresearch centers.

Biosafety Level 3 (BSL-3) Core is available for researchers whose work requires manipulation of biologicalagents which may cause serious or potentially lethal disease as a result of exposure by the inhalation route.

Cell Sorting Core assists users in adapting and modifying existing flow cytometric methods or to develop newprocedures for their specific requirements.

Center for Child Health Research is a national research institute created by the American Academy ofPediatrics, where particular attention is paid to the chronic conditions of childhood, children's mental health and

development, and the social and psychological determinants of child health.

Center for Future Health is a multidisciplinary research laboratory where physicians,engineers, and scientists create advanced medical technology on a personal scale.

Center for the Study of Rochester's Health is a collaborative research and teachingcenter with the mission of improving the health of Monroe County residents.

Center for Vaccine Biology and Immunology focuses on basic research intoimmunological mechanisms, and also on the long-term goal of helping to design the nextgeneration of vaccines.

Center for Visual Science is an internationally renowned research group dedicated to understanding theneural basis of vision.

Electron Microscope Imaging Core facility provides research support in electron microscopy using twomicroscopes: a Hitachi 7100 Electron Microscope and a Zeiss 902 microscope. In addition, a state-of-the-artscanning electron microscope will be acquired in the near future.

Functional Genomics Center is a comprehensive scientific and technological program that has been createdto serve the University of Rochester scientific community in addition to outside academic and industrial entitiesinterested in advancing biological and medical discovery using high-throughput genomics based technologies.

James P. Wilmot Cancer Center provides care, conducts significant cancer-related research, translatesadvances in the basic sciences into meaningful cancer treatments, and provides postdoctoral education.

MicroChemical Protein/Peptide Core Facility assists researchers by providing compositional and structuralelucidation of proteins and peptides.

5

U N I V E R S I T Y O F R O C H E S T E R

6

Nathan Shock Center conducts research into the basic biological processes of aging. The University's Center forAging and Developmental Biology is one of four recipients of a grant from the National Institute on Aging, declaringit a Nathan Shock Center of Excellence.

Nucleic Acid Core provides four types of services: DNA sequencing, oligonucleotide synthesis, genetic analysis,and Perkin-Elmer nucleic acid reagents.

Pathology/Morphology Imaging Facility provides a Leica Confocal Microscope, an Olympus FluorescentMicroscope, and an Arcturus PixCell Laser Capture Microscope for use by researchers. All users are provided theability and expertise to characterize normal and abnormal biologic specimens, from the level of the intact mouseto subcellular structures.

Real Time Confocal Core uses a Noran OZ real-time laser scanning confocalmicroscope and associated SGI computers for operating the instrument and for off-line data analysis.

Rochester Center for Biomedical Ultrasound is a unique environment toinvestigate the use of very high frequency soundwaves in medical diagnosis, along with other medical imaging and bioeffects research.

Schmitt Program on Integrative Brain Research is an interdisciplinary programsupporting activities in neuroscience that cross traditional disciplinary boundaries within three areas of focus: learning, plasticity, and memory; the senses and behavior;and the neurobiology of aging and disease.

Sleep Research Laboratory researches sleep and depression; mechanisms underlying the manifestation of sleep disorders; and the neuropsychological effects of sleep abnormalities.

Strong Children's Research Center is committed to improving child health byinvestigating the causes, prevention, and treatment of childhood diseases.

Transgenic Core provides expertise and assistance in the production of transgenic mouse models by either DNA microinjection or gene targeting inembryonic stem (ES) cells.

UNIVERSIT Y OF

ROCHESTER

MEDICAL CENTER

Patricia Rodier, Ph.D. and Christopher Stodgell, Ph.D.

M E D I C A L C E N T E R

B io me d i ca l D i s c o v er ie s a nd Te c h nolog ie s

f r o m the Un i v er s i ty o f Ro c he s ter

Cox-2 Gene Donald Young, M.D.

A research team at the University of Rochester led by Donald Young, M.D.discovered the cox-2 gene and revealed its role in causing inflammation withincells. The discovery set in motion a worldwide race among pharmaceuticalcompanies to identify drugs that would inhibit the action of the enzyme and, in turn, reduce inflammation and pain. In 2000, the university received a U.S.patent covering the use of the entire class of drugs known as cox-2 inhibitors,which includes the blockbuster arthritis medication Celebrex.

3-D Medical ImagingSaara Totterman, M.D., Ph.D. and Kevin Parker, Ph.D.

VirtualScopics, Inc. was founded in 1999 as a result of collaborative research between Saara Totterman, M.D., Ph.D.of the University of Rochester Medical Center and Kevin Parker, Ph.D. of the University’s School of Engineering andApplied Sciences. The team developed a technology that turns ordinary CT or MRI scans into 3-D color images andVirtualScopics created a suite of image tools used to detect and analyze specific body structures, as well as followchanges in tumors over time. Headquartered in Pittsford, NY, the company has 25 employees.

Cone Beam Volume Computed Tomography Ruola Ning, Ph.D.

Koning, Inc., headed by Ruola Ning, Ph.D., developed a 3-D Cone Beam Volume ComputedTomography that may significantly improve early detection of breast cancer and providenoninvasive diagnosis and treatment planning. The technology may also be used to visualizetiny lung tumors and to provide accurate 3-D images of vessels. While conventional CTtechnology provides spatial resolution of 1- 2 mm, Koning’s imaging technology is currentlyable to provide spatial resolution of structures smaller than 0.1 mm.

Neurodegenerative Diseases: Diagnosis and Therapeutics Berislav Zlokovic, M.D.

Socratech, Inc. is a company established by Berislav Zlokovic, M.D., Ph.D. to addressvascular aging and its relationship to neurodegenerative diseases by identifyingcritical vascular genes and developing drugs or diagnostics for those genes. Thecompany has raised $7 million of private financing and has 15 employees.

Light-Activated Gene Transduction Edward Schwarz, Ph.D.

Light-Activated Gene Transduction (LAGeT), developed by Edward Schwarz, Ph.D., uses gentle bursts of ultravioletlight to activate therapeutic genes that have been inserted into the cells. Through the use of laser light delivered viaa fiber optic cable, the technology may provide physicians with a means to control the location and the amount oftherapeutic gene expression. One application being developed is the activation of genes that cause cartilage togrow, which is likely to lead to a method to re-grow joint cartilage damaged by osteoarthritis.

7

Donald Young, M.D., Virginia Wynn, M.D., Ph.D. and Kerry O’Banion, M.D., Ph.D.

Amplicon Vaccine for HIVHoward Federoff, M.D., Ph.D.

Amplivex, Inc., a start-up founded by Howard Federoff, M.D., Ph.D., has re-engineered a herpes virus – stripping most of its DNA and replacing it withsmall snippets of DNA from the AIDS virus – in a bid to create a new type of AIDSvaccine. The approach harnesses one of the virus’ most useful features, calledan amplicon, which causes the virus’ DNA to be copied many times before itinfects a healthy cell. Early tests in mice suggest that the new vaccine couldhelp the immune system make more infection-fighting antibodies and killer T-cells than other vaccines, which could make it more effective.

HIV Drugs Targeting CEM-15 and VIFHarold Smith, Ph.D.

OyaGen, Inc., a start-up company established by Harold Smith, Ph.D., is working on a new class of HIV drugs thatmay enable the body's own immune system to virtually halt an HIV infection. The company's groundbreakingresearch centers on a crucial enzyme called CEM15. This "editing enzyme" slips inside a virus as it is beingassembled and later attacks or "edits" its DNA, producing DNA changes that disable the virus’ ability to replicate andinfect other cells. Unlike other viruses, HIV produces a protein called “vif” that neutralizes CEM15. Smith and hiscolleagues are testing a drug designed to prevent this neutralization of CEM15. In lab tests on HIV-infected cells, thedrug shielded CEM15 and enabled it to function normally, nearly halting the spread of the infection to other cells.

Blood Tests for Life Threatening Cardiac DisordersArthur Moss, M.D.

Arthur Moss, M.D. has identified a group of genes that are responsible forcardiac ion channel disorders including Familial Long QT Syndrome. Underan agreement with Genaissance Pharmaceuticals, Inc., Moss is helpingthe company to develop a genetic test for that disorder. Genaissancecurrently expects to market this genetic test to pediatric cardiologistsand electrophysiologists, to whom patients with such syndromes aregenerally referred. The test may assist physicians in choosing the mostappropriate course of treatment for each patient.

Telemedicine for the WorkplacePatricia Chiverton, Ed.D., R.N., FANP

Health CheckPoint, developed by Patricia Chiverton, Ed.D., R.N., FANP, is a telemedicine system that links theworkplace with health professionals. A computerized health station in the workplace allows employees to checktheir health conditions and helps establish routines to improve their health. The system tests blood pressure andother measures, and allows users to enter information about their health. That information is instantly transmittedvia telephone line or wireless link to a health-monitoring center, where RNs and other clinicians check results andadvise users as needed. The health station also provides web-based information on health problems such asdiabetes, high blood pressure, and smoking.

8

UNIVERSIT Y OF

ROCHESTER

MEDICAL CENTER

ROCHESTER INSTITUTE OF TECHNOLOGY (RIT)Internationally recognized as a world leader in career-oriented and professional education, Rochester Institute of Technology enrolls over 15,000 students in a wide range of technical programs.The university has a strong record of partnering with industry and government on applied researchand preparing students for technical and professional careers. In biotechnology and related fields, theuniversity’s expertise may be described under three major areas: the Center for BiotechnologyEducation and Training (CBET), Microsystems Research and Academic Programs and the InternationalCenter for Hearing and Speech Research. With its applied research focus, and its strong emphasis onworkforce development for emerging industries, RIT is uniquely positioned to be a tremendousresource and asset to companies as a university partner.

To focus the university on external partnerships, RIT President Dr. Albert J. Simone created the “First in Class” program in 1998. “First in Class” is a strategic initiative that invests in emergingtechnologies that will provide RIT partners, students, faculty, and the community with the technologyto be successful in a rapidly changing world.

“RIT intends to be first in that class of universities that forms real, effective and meaningfulpartnerships with industry and government.” — Dr. Albert J. Simone, President, Rochester Institute of Technology

1 Lomb Memorial Drive, Rochester, NY 14623 www.rit.eduFor information contact:

Deborah Stendardi, Vice President Government and Community Relations 585-475-5040 dmsgri@rit.eduBob Finnerty, Chief Communications Officer 585-475-4733 refuns@rit.edu

For information about “First in Class,” contact: Michael Dwyer, Director 585-475-2698 medpop@rit.edu

9

10

C enter f o r B io te c h nolog y Educatio n a nd Tra i n i ng ( C BE T )

Biotechnology is being called upon to address many of the greatest challenges to ever face humankind. RIT’ssuccess in meeting and overcoming these challenges will depend on a uniquely educated and technologicallyproficient workforce. Over its 175-year history, RIT has built its international reputation in the arena of workforcedevelopment through the creation of innovative, high technology, industry-driven programs.

RIT became a leader in life science education in 1983 when it launched thenation’s first Bachelor of Science program in biotechnology to prepare aworkforce with the specialized skills to meet the demands of a newindustry destined to become an economic powerhouse. It currently offersBachelor and Master of Science degrees in bioinformatics.

With a grant from the State of New York, RIT is currently designing a 38,000 square foot, state-of-the-art facility to house its new Center forBiotechnology Education and Training. CBET is targeted to open in late2005. CBET will continue RIT’s leadership role in biotech workforcedevelopment by creating innovative academic programs, specializedworkshops and seminars for industry partners, certificate trainingprograms for displaced workers seeking new career opportunities inbiotechnology, and unique industry/academic research collaborations todrive innovation and discovery for the future.

CBET’s Specialized Teaching and Training Laboratories will focus on the skills that lead to exciting careers.Traditional college students will share space with adult learners retraining for new careers and with middle andhigh school students discovering, perhaps for the very first time, a fascinating world of new opportunities. Some students will never set foot on campus, but will visit nonetheless through high-speed distance learningtechnology. These laboratories will reinforce RIT’s distinctive approach to opening the world of biotechnology tostudents of all ages.

“The CBET project is yet another example of the farsighted type of thinking that has become a hallmark of the RIT approach to education. RIT is a unique university system – both in scholastic merits and willingness to actively calibrate its academic programs to adjust to the needs of the local economy. Consequently, the Instituterepresents a ‘jewel’ in our region, ensuring that its graduates are well educated and well trained.” — Manager,

Environmental Health and Toxicology, Xerox Corporation

CBET’s Research Laboratories, designed for highly focused investigations, will foster the type of one-on-oneteaching that converts students into a new generation of scientists with a unique blend of education and practicalexperience needed to offer real world solutions to real world problems.

For information contact: Douglas Merrill, Ph.D., Associate Dean of the College of Science 585-475-2496 dpmsbi@rit.edu

Douglas Merrill, Ph.D., Associate Dean of RIT's College of Science, whose vision created CBET.

ROCHESTER

INSTITUTE OF

TECHNOLOGY

11

Mi c r o s ys tems Re s ea r ch a nd A cadem i c Pr og r a ms

Nanolithography and Potential Biomedical Applications

Bruce Smith, Ph.D., Associate Dean for Graduate Studies and Intel Professor ofMicroelectronic Engineering in the Kate Gleason College of Engineering at RIT, is leading aresearch team that has developed a breakthrough optical nanolithography technique.Using a prototype 193-nanometer liquid-immersion “microstepper” tool developed at RIT,optical image resolution at the smallest-ever level (down to 38 nanometers—highresolution previously possible only via extreme ultraviolet or near X-ray wavelengths) ismade possible. As a result, microchips can be produced with optics and light much closerto the ultraviolet range, making possible the development of smaller, faster and morepowerful microchips—with circuits 10 times smaller than possible from conventionalmethods—and more affordable micro- and nano-devices having smaller features.

The technology was unveiled at a workshop sponsored by International SEMATECH in Los Angeles in January, and has gained interest from firms such as Intel, IBM Corp., Motorola Inc. plus others. Potential biomedical applications include implantable medical devices and wearable computers for medical monitoring.

Smith, a member of the RIT faculty since 1988, is internationally known for his work in microlithography. Heholds numerous patents and, in 1999, was recognized with RIT’s first Creator’s Award for six patents, includingone for new coating materials used on photomasks to improve the resolution of computer chips. Prior to joiningRIT, Smith was a development engineer with Digital Equipment Corp. and Gould AMI Semiconductor. He alsoserved as president of Lithographic Technology Corp. from 1997 until 2001. He has numerous publications andco-wrote Microlithography: Science and Technology. Smith earned a Bachelor’s Degree and a Master’s Degree inphotographic and imaging science and a Doctoral Degree in imaging science, each from RIT.

The IT CollaboratoryIn 2003, New York State Office of Science Technology and Academic Research (NYSTAR) awarded RIT a grant to create The IT Collaboratory. The IT Collaboratory, a Strategically Targeted Academic Research Center funded bythe State of New York, brings together under one research enterprise RIT’s expertise in imaging, microsystems,photonics, materials and information technology, with an emphasis on integrating these disciplines to createand build systems. The mission of the Center, a collaborative effort among RIT, the University at Buffalo and theNYS College of Ceramics at Alfred University, is to develop the next generation of information technology systemsfor a wide range of applications including biomedical devices and instrumentation. It draws on the resources andexpertise of several RIT centers and laboratories including the Center for Imaging Science, the Laboratory forApplied Computing, the Nanopower Research Lab and the Semiconductor and Microsystems Fabrication Lab. TheIT Collaboratory research building will be built on campus beginning in 2004 and will create 22,000 square feetof dedicated research space adjacent to RIT’s existing 10,000 square foot clean room.

For information contact: Michael Dwyer, Director 585-475-2698 medpop@rit.edu

Center for Electronics Manufacturing and Assembly (CEMA)CEMA, in the College of Applied Science and Technology, is developing a project with City University of New York to develop a compact photonic explorer—a pill-sized devicethat, when swallowed, captures images from inside the human body. The device requires 12-millimeter circuit boards made by CEMA.

For information contact: Professor S. Manian Ramkumar 585-475-6081 smrnet@rit.edu

R O C H E S T E R

Bruce Smith, Ph.D.Microelectronics Professor, RIT

12

Biomedical Engineering RIT’s electrical engineering department, in the university’s Kate GleasonCollege of Engineering, offers a biomedical engineering option — a discipline crossing engineering with biology and medicine. The optiongives students expertise in the design of components for potentially life-saving medical devices used for critical-care monitoring, diagnostics,implantation and remote surgery.

Students study artificial intelligence, remote sensing and manipulation, wireless technology,microelectromechanical systems and fabrication. Biomedical engineering applications include online monitoringand diagnosis of cardiac function; invasive diagnostic devices; advanced prosthesis design using neural inputs;and “smart” sensors. Small, low-power, implantable medical devices, for example, can sense, process and control electrical signals.

Another area of study, telepresence for image analysis and surgery, uses instrumentation for detection andmanipulation in remote surgery or examination via remote communication and use of a robotic arm. BiomedicalInstrumentation, one of five courses in the option, teaches principles of electronic instrumentation and design forbiomedical measurement and monitoring devices. Other courses include Biomedical Sensors and Transducers,Fundamental Electrophysiology, Biomedical Signal Processing, and Biorobotics/Cybernetics.

For information contact: Professor Robert Bowman 585-475-2165 rjbeee@rit.edu

I nter natio na l C enter f o r Hea r i ng a nd S p e e c h Re s ea r c h

Age-related hearing loss, or presbycusis, affects about 28 millionAmericans. Those numbers expect to grow as the mass of baby boomersages. Rochester is a key national hub of research into the causes andperhaps cures for this ailment.

The International Center for Hearing and Speech Research, housed atRochester Institute of Technology, recently received a $6.3 million Federalgrant in 2003 to continue its work into the causes of age-related hearingloss. The Center is a joint effort between researchers at RIT and theUniversity of Rochester. As the home of the National Technical Institute forthe Deaf (NTID), RIT has extensive expertise in the area of deafness, whilethe University of Rochester brings its expertise in neuroscience and age-related research to the work of the Center. The NIH grant will extend for another five years the work that the Center started in 1989.

“Presbycusis research generally treats the ear as a stand-aloneorgan,” says NTID’s Dr. D. Robert Frisina, Director of the Center.The Center studies the brain and how it processes sounds, down to a cellular and molecular level. It is home to five different research efforts, each led by a different RIT or UR researcher who is trying tocharacterize presbycusis and pin down its causes. “One relatively new direction in the research,” Frisina says, “is genetics and gene therapy.”

Dr. D. Robert Frisina has been a pioneer in the field of deafness and hearing loss for more than 30 years.He first joined RIT in 1967 as Vice President and Organizing Director of NTID.

For information contact: Dr. D. Robert Frisina 585-475-6403 rfx1389@rit.edu

NTID researcher Dr. D. Robert Frisina Sr. on the left. His son, Robert Frisina Jr., Ph.D. on the right, is a professor of otolaryngology at the University of Rochester Medical Center.

Dr. D. Robert Frisina

I N S T I T U T E O F T E C H N O L O G Y

ROCHESTER

INSTITUTE OF

TECHNOLOGY

I N FOTO N I CS T E C H N O LO G Y C E N T E R O F E X C E LL E N C EThe Infotonics Technology Center, a collaborative industry, university and government initiative, is designed as aworld-class photonics and microsystems Center of Excellence. Infotonics accelerates innovative microsystemscommercialization through dedicated fabrication and packaging capability and strategic partners. The goal is toreduce the financial risk frequently associated with the development process and to increase the probability ofcommercial success. Featuring thousands of feet of clean room space, the facility will be capable of fabricating,packaging, and testing micro devices to be interconnected with the macroscopic world.

www.infotonics.orgFor information contact: Duncan T. Moore, Chief Executive Officer 585-919-3000 info@infotonics.org

T H E C E N T E R FO R E L E C T R O N I C I M A G I N G S Y S T E M S A N E W Y O R K S TAT E O F F I C E O F S C I E N C E , T E C H N O LO G Y A N D A C A D E M I C R E S E A R C H ( N Y S TA R ) D E S I G N AT E D C E N T E R FO R A D VA N C E D T E C H N O LO G YDevelops and transfers technology to industry for commercialization and educates the next generation of leadersin the fields of electronic imaging and microelectronics design.

www.ceis.rochester.eduFor information contact: Barry Watkins, Industry Liaison 585-273-2642 ceisweb@seas.rochester.edu

13

CENTERS

14

C O R N E LL A G R I C U LT U R E A N D FO O D T E C H N O LO G Y PA R KCornell University, the New York State Agricultural Experiment Station, Ontario County, the City of Geneva and New York State Electric and Gas (NYSEG) have worked as partners since 1995 to turn the vision of the 72-acreCornell Agriculture and Food Technology Park into reality. Located in Geneva, NY, the Park will fosteragriculture, food and bio-based technologies in the Finger Lakes by transferring cutting-edge research andtechnology to the private sector for commercial development, as well as attract private businesses andrelated scientific expertise. The Park is also expected to build unique alliances among Cornell and otheruniversities, State University of New York (SUNY) campuses, scientific institutions and economicdevelopment organizations. In addition, it will create up to 1,000 high-paying new jobs in Upstate New York.The groundbreaking for the Park was held on April 16, 2004.

www.nysaes.cornell.edu/adm/agtech/For information contact: Linda McCandless 315-787-2417 llm3@cornell.edu

CORNELL

AGRICULTURE

AND FOOD

TECHNOLOGY PARK

Summary:According to Jim Cortright with Impressa Consulting, “Biotech has emerged as an icon of technology,but the industry is not likely to produce a lot of new giants. Firms in the industry gain an advantage bylocating near other firms in the industry. Talent is drawn to where the firms are — and firms formwhere the talent is. Biotech tends to cluster and leaders have an edge.”

Clustering in Key Markets: Biotech companies tend to cluster where firms and support are already established for idea sharing,infrastructure, talent and resources. Nine large metro areas contain 75% of the biotechnology firmsformed within the past 10 years. Biotech investment has been targeted within these nine markets foralmost 30 years, and they account for 60% of NIH research spending. The Top Five Biotech Metros:Boston, San Francisco, San Diego, Seattle and Raleigh-Durham accounted for three-fourths of biotechventure capital over the past six years. (Brookings Institution, 2003).

New Markets Being Considered: Although biotech has historically been one of the most concentrated industries, companies areconsidering operations in new market locations. This trend is being driven by stronger attractionefforts by cities and states, and companies desire to operate in areas with high productivity. However, the need to be in relative proximity to major market activity remains a key factor.

Pharmaceuticals Clustered: Pharmaceutical firms still tend to cluster in core geographic locations, including NY/Northern NJ;Philadelphia/Southern NJ; Los Angeles, and San Francisco.

Common Target: In 2001, a Department of Commerce survey found that more than 80% of state/municipalityrespondents listed biotech as one of their top two targets for development. According to the BatelleInstitute for BIO, 41 states have programs aimed at spurring life sciences.

Tough to Break-In: Because the nine largest bio cluster metro areas have such a headstart on the others, many expertsbelieve it will be very difficult for other metro areas to break into the market.

Niche: Many experts believe a niche is necessary for mid-size markets to succeed in biotech. Raleigh-Durham has focused on drug manufacturing; New Mexico on bioinformatics; Iowa on its agricultural and veterinary biotech; and Pittsburgh hopes to capitalize on tissueengineering and medical devices.

15

L O C A T I O N T R E N D S

E C O N O M I C D E V E L O P M E N T T R E N D S

N a t i o n a l I n d u s t r y Tr e n d s

Small Industry: Biotechnology remains a small industry, with only about 1,400 firms and180,000 jobs nationwide.

Low Success Rate:The Biotechnology Industry Organization (BIO) estimates it takes firms 15 yearson average to become profitable.

Small Firms: Biotech firms are seldom among the top 25 employers in any given market. Most biotech firms are small, and often successful firms sell or license productsto large pharmaceutical companies.

Patents/Potential Industry Growth:In 2001, the U.S. Department of Commerce conducted a survey of over 1,000 U.S. biotech firms, and found that those firms held almost 24,000 patents and had more than 33,000 patents pending. This indicates an industry poised for growth.

Convergence: Various technology sectors are converging to create a large multi-disciplined Life Science Industry. These include: biological processes; pharmaceuticals; medical devices; nanotechnologies; and information technology.

Mergers and Acquisitions:The need for large pharmaceutical firms to keep their R&D pipelines full, combined with the needs of small biotech firms to secure capital to commercialize their products, creates an environment that is ripe for merger and acquisition activity.

Top Policy Barriers: A recent Commerce Department survey identified the following biotech-related policyconcerns: Regulatory approval process; Research costs; Start-up capital; Third-party patent rights; Patent fees and the approval process.

• The mapping of the human genome is largely complete.

• The FDA is accelerating new drug approval, including the implementation of a fast-track approval program forurgently needed therapies.

• There is a convergence of nanotechnology (the creation of very tiny devices) with biotechnology. Technologies developed for the biotech market are now leveraging into uses for entirely new areas such asmolecular electronics.

• Advanced computer technology has led to high-speed laboratory techniques.

• Immense databases have created a new sector, referred to as “bioinformatics,” whereby basic research data isnow widely available to scientists around the globe.

• Partnerships and collaboration among biotech start-ups, major drug manufacturers, and the researchdepartments at major universities are at an all-time high.

• Among the most important factors: a veritable frenzy of new financing has poured into the biotech industry —funding aggressive research, development, and marketing plans.

• Advanced imaging techniques.

• Biotech and advanced pharmaceutical uses grow while costs soar.

• Advanced information technology and medical records technology.

• Stem cells and other biotech advances create controversy.

Source: Plunkett Research, as seen in Hoover’s Online16

NATIONAL

INDUSTRY TRENDS

I n c enti v e s a nd Fi na n c i ng f o r B io te c h nolog y a nd L i fe S c ien c e s Fi r ms

Empire State Development (ESD) has developed a variety of incentives designed to meet the changing needs ofemerging growth companies in New York State and target the biotechnology and life sciences industry.

Biotechnology Industry Growth Fund — As of 2000-01, New York State's Budget provided $10 million in newfunding for biotechnology development at research and manufacturing facilities, including support for theconstruction and business capital for small and start-up biotech companies to commercialize innovations thatemerge from the laboratory. The Fund money was apportioned to ESD ($5 million) for business assistance and to NYSTAR ($5 million) for research and universities.

Biotechnology Investment Refundable Tax Credit — Effective 1/1/2001, this measure expanded the ITC tobiotech companies, thereby fostering the growth of these companies and stimulating job creation.

As of 1/1/99, two new credits became available for emerging technology companies, as part of theEmerging Industries Jobs Act:

Qualified Emerging Technology Employment Credit — A credit of $1,000 per new full-time employee(employees in excess of 100% of base year employment level), available for one three-year period (the year thecredit is first claimed and in each of the next two years) provided minimum employment levels are maintained.Unused credits can be carried forward indefinitely; new businesses (NY taxpayers for less than six years oreight years if business is subject to Federal regulatory approval) can take a refund of unused credits.

Qualified Emerging Technology Company Capital Tax Credit — A taxpayer is allowed a credit equal to apercentage of each qualified investment in a qualified emerging technology company and certified by theCommissioner of Taxation and Finance as follows:

10% of qualified investments, provided the taxpayer certifies that the qualified investment will not be sold, transferred, traded, or disposed of during the four years following the year in which the credit is first claimed; or20% of qualified investments, provided the taxpayer certifies that the qualified investment will not besold, transferred, traded, or disposed of during the nine years following the year in which the credit is first claimed.

High-Tech Revolving Loan Fund —The Rochester Economic Development Corporation's (REDCO) High-TechRevolving Loan Fund's objective is to assist with job creation or retention in the city by providing low interestloans to technology companies. Loan amounts will not exceed $250,000. Loan proceeds can be used for thefollowing: real estate acquisition, building construction and/or renovation; purchase and installation ofequipment (software and hardware) and working capital. Businesses eligible to use the loan fund include:Biotechnology and Medical Technology, Photonics and Optics, Telecommunications, Electronic Commerce, andInformation Technology organizations.

The City of Rochester's Economic Development Department also works with local developers to providecompetitive space for high-tech firms.

17

INCENTIV

ES AND

FINANCIN

G

16

ABgene Inc. USA Tel: 800-445-2812565 Blossom Road Fax: 585-654-4810Rochester, NY 14610 www.abgene.com

ABgene® is a subsidiary of Apogent Technologies Inc., a developer and manufacturer of value-added products for theclinical and research markets. The company's customers include distributors, pharmaceutical and biotechnologycompanies, clinical, research and industrial laboratories and original equipment manufacturers (OEMs). ABgene®produces a diverse range of molecular biology reagents, plastic consumables and instrumentation, enabling it to offer complete product solutions.

Bausch & Lomb World Headquarters Tel: 585-338-6000One Bausch & Lomb Place Fax: 585-338-6007Rochester, NY 14604-2701 www.bausch.com

Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing life for consumers aroundthe world. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, as well as ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is one of the best known and mostrespected healthcare brands in the world. The company, which celebrated its 150th anniversary in 2003, isheadquartered in Rochester, NY. Bausch & Lomb's 2002 revenues were $1.8 billion; it employs approximately 11,500 people worldwide and its products are available in more than 100 countries.

Biocube LLC Tel: 877-299-2108 100 Rawson Road Fax: 585-924-8280Victor, NY 14564 www.biocube.com

When it comes to solving an odor problem, the first step is to identify the odor causing compounds. The Biocube™Biofilter has revolutionized the process of biofiltration with its patented modular tray design that eliminates all theproblems associated with traditional in-ground biofilters. The result is a biofiltration system that works reliably andvirtually maintenance free. With total control over the process conditions, it is capable of much higher productivity andefficiency than has been possible in the past.

Biophan Technologies, Inc. Tel: 585-214-2441150 Lucius Gordon Drive, Suite 215 Fax: 585-427-2433West Henrietta, NY 14586 www.biophan.com

Biophan Technologies, Inc. provides solutions that make biomedical devices safe for usewith magnetic resonance imaging (MRI) devices as well as reduce the interference thesedevices cause to the quality of MRI images. The solutions include coatings, filters andphotonics — and can be applied to a wide range of implanted biomedical devices, inaddition to those used in surgical and diagnostic procedures (interventional medicine).The company holds nine issued and over fifty pending patents covering these solutions.

Preparing for upcoming experiments in an active magnetic resonance imaging (MRI) system, Biophanresearchers discuss their test sample and experimental set-up. Left to right, Physicist Bob Gray explains themeasurements to be made to Stu MacDonald, VP Research and Development and Jeff Helfer, VP Engineering.These experiments assess improvements Biophan is developing that will permit people with pacemakers andother implanted medical devices to be safely imaged using MRI.

18

To p Re g io na l B io te c h nolog y a nd L i fe S c ien c e s C o mp a n ie s

TOPREGIONAL

COMPANIES

BioWorks, Inc. Tel: 800-877-9443345 Woodcliff Drive Fax: 800-903-2377Fairport, NY 14450 www.bioworksbiocontrol.com

BioWorks is a supplier to the agriculture industry of biological control products and biotechnologies that enhance plant health, plant productivity and consumer and worker safety. Utilizing intellectual properties obtained under anexclusive licensing agreement with Cornell Research Foundation, an affiliate of Cornell University, the companycurrently develops, manufactures and markets fungal based biocontrol products. BioWorks' products and intellectualproperty portfolio are derived from strains of naturally occurring, soil-based microorganisms which have the ability tocontrol harmful fungi that attack a plant's roots.

Bruker Daltonics Inc. Tel: 315-966-0060 4056 Boynton Road Fax: 315-966-0061Walworth, NY 14569-9712 www.bdal.com

Bruker Daltonics develops innovative life science tools based on mass spectrometry. Its substantial R&D investment allows the company to design, manufacture and market a broad array of novel products forpharmaceutical, biotechnology, proteomics, and molecular diagnostics companies, along with academic institutions and government agencies. Diverse technology platformsintegrate automated sample preparation and clean-up, advanced front-endAnchorChip MALDI targets and API source technology with cutting-edgeproprietary MALDI-TOF, MALDI-TOF/TOF, ESI-TOF, ESI-Q-q-TOF, ion trap and Q-q-FTMS mass analyzers, plus analysis and bioinformatics software.

CPAC Imaging Inc. Tel: 585-382-23542364 Leicester Road Fax: 585-382-3031Leicester, NY 14481 www.cpacimaging.com

Since 1969, CPAC Imaging has led the field in Diagnostic Imaging, offering a comprehensive product line for wetprocesses including chemistries, mixers, processor cleaning/maintenance supplies, silver recovery andenvironmental compliance equipment, illuminators, and silver refining services. As the largest independent U.S.manufacturer of medical X-ray chemistry, the company’s premium Autex® brand offers universal chemistries for all applications and modalities. Its products are manufactured on four continents and sold in over 100 countries to medical, dental,photographic, and graphic arts professionals.

19

The new Bruker Metabolic Profiler™ researchsystem is ideal for the study of disease,

drugs, and other biologically active molecules.

Autex® Chemistry – Suitable for all types of films,extremely clean-working, and formulated for long

shelf life, these concentrated liquids deliversuperior performance and convenience.

Celltech Pharmaceuticals, Inc. Tel: 585-274-5656755 Jefferson Road Fax: 585-274-3918Rochester, NY 14623 www.celltechgroup.com

Celltech Group PLC is a European-based biotechnology company located in Henrietta, NY. Celltech’scommitment to innovative drug discovery and development, combined with its extensive productpipeline, position the company for sustained growth as a global biotechnology leader. Celltechmanufactures and distributes medications at its Henrietta facility, where the patented Pennkinetic,resin-based technology for producing drugs with extended-release properties, was originated.Among its comprehensive portfolio, Celltech medications manufactured in Rochester treat thecentral nervous system and respiratory diseases.

CooperVision200 WillowBrook Office Park Tel: 585-385-6810Fairport, NY 14450 www.coopervision.com

CooperVision is a rapidly growing specialty healthcare company. Its two business units serve attractive niche marketsin the medical device market with high quality, proprietary products. CooperVision (CVI) markets a broad range ofcontact lenses throughout the world. CooperSurgical (CSI) markets diagnostic products, surgical instruments andaccessories for the women’s healthcare market. A contact lens pioneer for decades, CooperVision has become thefourth-largest contact lens maker in the world and the number one manufacturer of toric lenses.

Electro Surgical Instrument Company Tel: 888-464-278437 Centennial Street Fax: 585-235-1438Rochester, NY 14611 www.electrosurgicalinstrument.com

Electro Surgical Instrument Company has been providing lighted surgical instruments to a variety of surgical specialists for 108 years. The original instruments utilized theminiature incandescent lamp for illumination. In the 1970s, the company began toilluminate using optical glass fibers. In addition to a standard line of instrumentation, thecompany also provides custom design and modification services. All manufacturing isconducted at the Rochester, NY facility.

Genencor International, Inc. Tel: 585-277-43001700 Lexington Avenue Fax: 585-277-4302 Rochester, NY 14606-3140 www.genencor.com

Genencor International is a diversified biotechnology company with over $380 million in revenues in 2003. Genencorfocuses on two markets: bioproducts and healthcare. For the bioproducts market, Genencor discovers, develops, andsells biocatalysts and other biochemicals for the industrial, consumer, and agri-processing markets. For the healthcaremarket, Genencor has drug development platforms in protein therapeutics and immunotherapeutics targeting viralinfectious diseases and cancer.

Getinge USA Inc. 1777 East Henrietta Road Tel: 585-475-9040 Rochester, NY 14623-3133 www.getingeusa.com

Getinge is a leading global provider of equipment and systems to customers within healthcare, extended care andpharmaceutical industries/laboratories. Equipment, services and technologies for infection control, operating theatres,patient hygiene, patient handling and wound care are supplied to customers throughout the world. The company’sproducts and services contribute in a tangible way to quality enhancement and reduction of customers' costs.

20

TOPREGIONAL

COMPANIES

The founders of Electro Surgical Instrument Company invented the miniature lampto be used for illumination of both surgical and diagnostic instruments. For the

first time, physicians could clearly view inside the body through natural openings.

Tussionex and Delsym, Celltech’s 12-hour acting cough/cold products, continue to perform strongly in themarketplace. In addition, Metadate CD, indicated for attention deficit hyperactivity disorder (ADHD) continues to behighly profitable for the company. Dipentum, acquired by Celltech in 2002, covers approximately half of theprescribing base for currently marketed biological products in Crohn’s disease.

21

Integrated Nano-Technologies Tel: 585-334-0170999 Lehigh Station Road Fax: 585-334-0176Henrietta, NY 14467 www.integratednano.com

Integrated Nano-Technologies is a progressive development company focusing on a uniquefusion of molecular biology, chemistry and microelectronics to produce revolutionary technicaladvances. With this foundation, the company has developed solutions to some of the greatestchallenges currently facing the biosecurity and clinical diagnosticsmarkets. The initial product is a rapid, accurate, field-portableelectronic DNA identification platform called BioDetect. As thecompany grows, additional developments in nano-scaleelectronics, structures and materials are planned.

Eastman Kodak Company Health Imaging343 State Street Tel: 585-724-7206Rochester, NY 14650-1132 www.kodak.com/go/health

Kodak's Health Imaging Group is a world leader in developing, manufacturing andmarketing intelligent imaging products from analog to digital. Its portfolio includescomputed radiography (CR) and digital radiography (DR) systems, laser imagers, picturearchiving and communications systems (PACS), radiology information systems (RIS),traditional mammography systems, X-ray film systems for general radiography, dentalimaging products and numerous services offerings. The group, with 2003 revenues of$2.43 billion, has served the global healthcare community for more than 100 years.

LSI Solutions Tel: 585-742-8086 7796 Victor-Mendon Road Fax: 585-869-6600 Victor, NY 14564 www.lsisolutions.com

LSI Solutions is a fully integrated medical device research, design, manufacturing, marketing and sales company dedicated to providing innovative solutions and proprietary products for the advancement of minimally invasive therapeutic procedures.

Litron Laboratories Inc.1351 Mount Hope Avenue #207 Tel: 585-442-0930Rochester, NY 14620 www.LitronLabs.com

Through constant innovation, Litron assures the safety of its clients' pharmaceuticals, medical devices, inks, toners and other discoveries while helping bring these valuable products to market faster. From the customer’s firstassay during product development to their final submission for regulatory approval, Litron has the practices and thepeople customers can trust. The company’s staff performs all genetic toxicology tests following standard protocolsthat meet or exceed the requirements of domestic and international regulatory agencies including FDA, EPA, OECD,and ICH, among others. Litron has extensive experience conducting genotoxicity studies in accordance with GoodLaboratory Practice (GLP) guidelines — and the company’s Quality Assurance Unit ensures the integrity of all GLPstudies in its laboratories.

In addition to providing excellent imagequality and productivity, Kodak'scomputed radiography (CR) and digitalradiography (DR) digital image capturesystems support healthcare providers'transition to a digital environment forthe efficient storage, management anddistribution of patient medical images.

KODAK DIRECTVIEW PACS System 5 is an image-and-information management system that enables radiology

departments to store, view and manage large volumes ofmedical images and information. Fully Web-enabled,

Kodak's PACS makes it possible to distribute informationfrom one location to another electronically – via the

Internet – thus facilitating and expediting communicationsbetween radiologists and referring physicians.

BioDetect Single Use Test Card –Provides electronic DNA testingfor single or multiple organisms.

BioDetect Analyzer – Usedfor processing test cards.

TOPREGIONAL

COMPANIESMed Graph, Inc.53 Glenside Way Tel: 585-453-9437Rochester, NY 14612 www.med-graph.com

Med Graph is dedicated to advancing medical informatics as the single most important innovation that cansimultaneously achieve better patient care at reduced healthcare cost, while providing yet unexplored researchopportunities. The company’s long-term objective is to deploy innovative medical informatics processes and systems,ultimately resulting in a visual key health indicator "report card" for all an individual’s biometrics accessible anytime,anywhere. Med Graph holds issued patents on electronic communications of medical diagnostic information that are atthe forefront in this area of medical informatics.

Ortho-Clinical Diagnostics (a Johnson & Johnson company) 100 Indego Creek Drive Tel: 800-828-6316Rochester, NY 14626 www.orthoclinical.com

Ortho-Clinical Diagnostics, a Johnson & Johnson company, is a leading provider of high-value diagnostic products andservices for the global healthcare community. For more than half a century, the company has been committed toproviding accurate, timely, and cost-effective solutions for screening, diagnosing, monitoring and confirming diseases.The company combines an on-going investment in technological innovation and product quality with an unparalleledfocus on customer service and support. Its patented dry slide and enhanced chemiluminescence technologies havetransformed the way that clinical laboratories perform testing, and since 1985 the company has been ranked numberone for superior service and customer support.

PharmaNova Tel: 585-214-0588150 Lucius Gordon Drive Suite 206 Fax: 585-427-7455West Henrietta, NY 14586 www.PharmaNovaCo.com

PharmaNova, a specialty biopharmaceuticals company, applies proprietary drug delivery andformulation technologies to existing drugs to develop improved medicines in the fields ofwomen’s health, oncology, and dysphagia. The company is seeking partners to license andfacilitate the development of Xenolev®, a non-hormonal prescription drug alternative to women’s hormone therapy to alleviate the symptoms of menopause such as hot flashes aswell as NanoPavol®, a stable injectable nanoparticle formulation of paclitaxel without solubilizers such as “Chremophor” for oncology patients.

SPS Medical Supply Corp. Tel: 800-722-15296789 West Henrietta Road Fax: 585-359-0167Rush, NY 14543 www.spsmedical.com

SPS Medical is the largest sterilizer testing laboratory in North America and is a corporate member of AAMI (medical) and OSAP (dental). Having private labeled in past years to other companies, the company provides the industry's most complete line of sterility assurance products under its brand through authorized distributors worldwide. With an experienced staff and over 45 sterilizers, SPS Medical offers a wide range of sterilization consulting and testing services to medical device manufacturers.

STS Biopolymers Inc. Tel: 585-321-1130336 Summit Point Drive Fax: 585-321-1575Henrietta, NY 14467 www.medi-coat.com

Since 1991, STS Biopolymers has been developing and manufacturing state-of-the-art biocompatible coatings for medical devices and providing contract coating services to medical device manufacturers. The company’s coatingsare in commercial use on a wide range of medical devices including vascular and neurointerventional catheters andguidewires, dilators, cannulae, gastroenteral feeding tubes, urinary catheters and guidewires, blood filters, infusioncatheters and stents.

Microphotograph of paclitaxel nanoparticles in blood.

22

23

STS duoTEK, Inc.370 Summit Point Drive Tel: 800-836-4850Henrietta, NY 14467 www.stsduotek.com

STS has provided laboratory testing (biocompatibility, toxicology, microbiology, reusable medical devices, andanalytical chemistry); contract sterilization (ethylene oxide and steam); assembly and packaging services as well asbiological indicators, to medical device and pharmaceutical manufacturers since 1979. Accuracy, quality, timelinessand confidentiality are of the utmost importance to the company and its clients.

Tel-e-Atrics, Inc. Tel: 585-292-7010150 Lucius Gordon Drive Suite 100 Fax: 585-272-0054West Henrietta, NY 14586 www.teleatrics.com

Tel-e-Atrics, a program conceived by physicians, connects doctors, nurses and other members of the healthcare teamwith their patients wherever they may be — school, childcare, workplace, camp, recreational facilities, home, medicaloffice or hospital. Using high quality videoconferencing and digital medical cameras as well as other diagnosticequipment, medical evaluations and treatment plans for a broad range of problems may be completed andimplications discussed face-to-face, while providers and patients remain miles apart.

Vaccinex, Inc. Tel: 585-271-2700 1895 Mount Hope Avenue Fax: 585-271-2766 Rochester, NY 14620 www.vaccinex.com

Vaccinex is engaged in the discovery and development of novel therapeutic antibodies, one of the fastest growing segments of the biopharmaceutical market. The company’s proprietary technology offers the ability to discover fully humanantibodies against targets that are difficult or impossible to address with other platforms. Vaccinex is currently developing an antibody product pipeline and offersantibody discovery services to others. Vaccinex has received over $23M in venturefunding and research grants and employs 38 individuals.

VirtualScopics LLC Tel: 585-249-6237350 Linden Oaks Fax: 585-218-7350Rochester, NY 14625 www.virtualscopics.com

VirtualScopics provides medical image analysis services for pharmaceutical and medical device clinical trials. Thecompany’s suite of image analysis tools detect and analyze specific structures in volumetric medical images using 3-D models of tissues and organs in the body to quantify and track the progress of various diseases, includingmultiple sclerosis, osteoarthritis, rheumatoid arthritis and cancer. These tools also characterize minute changes instructures over time, with an eye toward applications in both clinical research and diagnostics.

Xerox Corporation 1-800-ASK-XEROX ext 972 100 South Clinton Avenue Fax: 585-423-4272 Rochester, NY 14644 www.xerox.com

Xerox spends about $1 billion annually on research and development. The Xerox Innovation Group explores theunknown, invents next-generation technology, architects product platforms, manages intellectual property, andcreates new business opportunities through its research centers and associated operations. Xerox offers a number ofmaterials technologies that are available for license such as Ferrofluids — nanoscale magnetic particles dispersed insolvents such as water or alcohol — that could be used in biotechnology, electronics, optical switching and securityapplications. Xerox Particle Simulation Environment — a 3-D modeling software developed to help scientists build andmanipulate particulate materials — is another offering.

TOP

REGIONAL

COMPANIES

C O M P A N I E S W E B S I T E A D D R E S S

ABgene Inc. USA www.abgene.com

Advanced Glass Industries www.advancedglass.net

Bausch & Lomb www.bausch.com

Biocube, LLC www.biocube.com

Biophan Technologies, Inc. www.biophan.com

BioWorks, Inc. www.bioworksbiocontrol.com

Bruker Daltonics Inc. www.bdal.com

CPAC Imaging Inc. www.cpacimaging.com

Celltech Pharmaceuticals, Inc. www.celltechgroup.com

Cleanroom Consulting LLC www.cleanroom-consulting.com

CooperVision Inc. www.coopervision.com

Electro Surgical Instrument Company www.electrosurgicalinstrument.com

Enslein Research Inc. www.enres.com

Gambro Healthcare www.gambrohealthcare.com

Genencor International, Inc. www.genencor.com

Getinge USA Inc. www.getingeusa.com

Integrated Nano-Technologies www.integratednano.com

Eastman Kodak Company Health Imaging www.kodak.com/go/health

LSI Solutions www.lsisolutions.com

Lake Immunogenics www.lakeimmunogenics.com

Litron Laboratories Inc. www.LitronLabs.com

Med Graph, Inc. www.med-graph.com

Ortho-Clinical Diagnostics, a Johnson & Johnson Co. www.orthoclinical.com

PharmaNova www.PharmaNovaCo.com

SPS Medical Supply Corp. www.spsmedical.com

STS Biopolymers Inc. www.medi-coat.com

STS duoTEK, Inc. www.stsduotek.com

Tel-e-Atrics, Inc. www.teleatrics.com

Vaccinex, Inc. www.vaccinex.com

VirtualScopics LLC www.virtualscopics.com

Xerox Corporation www.xerox.com

RESEARCH FACILITIES AND EDUCATIONAL INSTITUTIONS

Center for Electronic Imaging Systems www.ceis.rochester.edu

Cornell Agriculture and Food Technology Park www.nysaes.cornell.edu/adm/agtech/

Infotonics Technology Center www.infotonics.org

Rochester Institute of Technology www.rit.edu

University of Rochester Medical Center www.urmc.rochester.edu

6/04

100 Chestnut Street

One HSBC Plaza Suite 1910

Rochester, NY 14604

Phone: 585.530.6200 • Fax: 585.546-8477

info@GreaterRochesterEnterprise.com

www.GreaterRochesterEnterprise.com

MADE FOR BUSINESS • MADE FOR LIVING • MADE FOR YOU